[
  {
    "ts": null,
    "headline": "European Medicines Agency Adopts a Positive Opinion on ​Regeneron’s (REGN) Libtayo",
    "summary": "​Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy Right Now. On October 17, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the European Medicines Agency adopted a positive opinion for its Libtayo, which treats adults with cutaneous squamous cell carcinoma. Earlier this month, Libtayo was approved by the FDA to […]",
    "url": "https://finnhub.io/api/news?id=647b842fbfa491812c48736c869b4d516febb33ea77c6a8fa6b67006973274ec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761477912,
      "headline": "European Medicines Agency Adopts a Positive Opinion on ​Regeneron’s (REGN) Libtayo",
      "id": 137217204,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "​Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy Right Now. On October 17, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the European Medicines Agency adopted a positive opinion for its Libtayo, which treats adults with cutaneous squamous cell carcinoma. Earlier this month, Libtayo was approved by the FDA to […]",
      "url": "https://finnhub.io/api/news?id=647b842fbfa491812c48736c869b4d516febb33ea77c6a8fa6b67006973274ec"
    }
  }
]